Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
Barzin Y. Nabet(Gene Therapy Laboratory), Maximilian Diehn(Stanford University), Taha Merghoub(Cornell University), Hira Rizvi(Memorial Sloan Kettering Cancer Center), Ash A. Alizadeh(California Institute for Regenerative Medicine), Mohammad Shahrokh Esfahani(Stanford Medicine), Diane Tseng(Stanford University), Young-Jun Jeon(Stanford University), Kavitha Ramchandran(Stanford University), Everett J. Moding(Stanford Medicine), Matthew D. Hellmann(AstraZeneca (United States)), Emily G. Hamilton(Stanford University), Joel W. Neal(Stanford Medicine), Heather A. Wakelee(Palo Alto Institute), Rene F. Bonilla(Stanford University), Andrew J. Plodkowski(Memorial Sloan Kettering Cancer Center), Christopher H. Yoo(Stanford University), Chih Long Liu(Stanford University), Henning Stehr(Stanford University), Ryan B. Ko(Stanford University), Sukhmani K. Padda(Stanford University), Millie Das(VA Palo Alto Health Care System), Chloé B. Steen(Stanford University), Linda Gojenola(Stanford University), Cailian Liu(Memorial Sloan Kettering Cancer Center), Aadel A. Chaudhuri(Washington University in St. Louis), Jacob J. Chabon(Foresight Science & Technology (United States)), Diego Almanza(Stanford University), Michael C. Jin(Stanford University), Emily Chen, Angela Bik‐Yu Hui(Stanford University), Aaron M. Newman(California Institute for Regenerative Medicine)
Cited by 360
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k